ABSCI CORP APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ABSCI CORP (ABSI) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- ABSCI CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.54M, a 4.57% decline year-over-year.
- ABSCI CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.39M, a 10.60% decline year-over-year.
- ABSCI CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.38M, a 20.15% decline year-over-year.
- ABSCI CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.75M, a 11.23% decline year-over-year.
- ABSCI CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $18.29M, a 6.08% decline from fiscal 2024.
- ABSCI CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $19.47M, a 71.07% increase from fiscal 2023.
- ABSCI CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $11.38M, a 10.10% decline from fiscal 2022.
- ABSCI CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $12.66M, a 27.49% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.54M 10-Q · filed 2026-08-11 | $8.93M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $4.39M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $18.29M 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $4.38M 10-Q · filed 2025-11-12 | $9.14M derived: sum of 2 quarters · filed 2026-08-11 | $14.05M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $4.75M 10-Q · filed 2026-08-11 | $9.66M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $4.91M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $19.47M 10-K · filed 2026-03-24 | |||
| 2024-09-30 | $5.49M 10-Q · filed 2025-11-12 | $10.84M derived: sum of 2 quarters · filed 2025-11-12 | $14.39M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $5.35M 10-Q · filed 2025-11-12 | $8.90M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $3.54M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $11.38M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | $2.54M 10-Q · filed 2024-11-12 | $5.58M derived: sum of 2 quarters · filed 2024-11-12 | $8.24M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $3.04M 10-Q · filed 2024-11-12 | $5.69M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $2.65M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $12.66M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $3.76M 10-Q · filed 2023-11-14 | $7.96M derived: sum of 2 quarters · filed 2023-11-14 | $11.64M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $4.20M 10-Q · filed 2023-11-14 | $7.88M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $3.68M 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $9.93M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $3.73M 10-Q · filed 2022-11-09 | $5.22M derived: sum of 2 quarters · filed 2022-11-09 | $6.74M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $1.49M 10-Q · filed 2022-11-09 | $3.01M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $1.52M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $420.00K 10-K · filed 2022-03-22 | |||
| 2020-09-30 | $86.00K 10-Q · filed 2021-11-09 | $144.00K derived: sum of 2 quarters · filed 2021-11-09 | $152.00K derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $58.00K 10-Q · filed 2021-11-09 | $66.00K derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $8.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |